glp-1-based treatments approved for weight loss 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ GLP-1s reduce weight, with investigational
Description
Playing with Doug
Ideal for those seeking current, actionable clinical strategies for metabolic health and private practice growth
It looks like a hemodynamic effect
In orforgliprons study, up to 10% of patients stopped treatment, compared with 3% on placebo
To ensure methodological rigor, inter-coder reliability was systematically assessed
doi: 10.1038/379606a0 20
